Format

Send to

Choose Destination
PLoS One. 2017 Aug 21;12(8):e0183586. doi: 10.1371/journal.pone.0183586. eCollection 2017.

Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis.

Chen R1, Chan PT2, Chu H3,4,5, Lin YC1,6, Chang PC1, Chen CY6,7,8, Chou KR1,9,10.

Author information

1
School of Nursing, College of Nursing, Taipei Medical University, Taipei, Taiwan.
2
Department of Nursing, En Chu Kong Hospital, Taipei, Taiwan.
3
Aviation Physiology Research Laboratory, Kaohsiung Armed Forces General Hospital Gangshan Branch, Kaohsiung, Taiwan.
4
Institute of Aerospace and Undersea Medicine, School of Medicine, National Defense Medical Center, Taipei, Taiwan.
5
Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
6
Department of Anesthesiology, Taipei Medical University Hospital, Taipei, Taiwan.
7
Department of Anesthesiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
8
Graduate Institute of Humanities in Medicine, Taipei Medical University, Taipei, Taiwan.
9
Department of Nursing, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan.
10
Psychiatric Research Center, Taipei Medical University Hospital, Taipei, Taiwan.

Abstract

BACKGROUND:

This is the first meta-analysis to compare the treatment effects and safety of administering donepezil alone versus a combination of memantine and donepezil to treat patients with moderate to severe Alzheimer Disease, particularly regarding cognitive functions, behavioral and psychological symptoms in dementia (BPSD), and global functions.

METHODS:

PubMed, Medline, Embase, PsycINFO, and Cochrane databases were used to search for English and non-English articles for inclusion in the meta-analysis to evaluate the effect size and incidence of adverse drug reactions of different treatments.

RESULTS:

Compared with patients who received donepezil alone, those who received donepezil in combination with memantine exhibited limited improvements in cognitive functions (g = 0.378, p < .001), BPSD (g = -0.878, p < .001) and global functions (g = -0.585, p = .004). Gradual titration of memantine plus a fixed dose and gradual titration of donepezil as well as a fixed dose and gradual titration of memantine resulted in limited improvements in cognitive functions(g = 0.371, p = .005), BPSD(g = -0.913, p = .001), and global functions(g = -0.371, p = .001).

CONCLUSION:

Both in the 24th week and at the final evaluation point, the combination of donepezil and memantine led to greater improvement in cognitive functions, BPSD, and global functions than did donepezil alone in patients with moderate to severe Alzheimer Disease.

PMID:
28827830
PMCID:
PMC5565113
DOI:
10.1371/journal.pone.0183586
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center